Literature DB >> 3361379

Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.

B A Claesson1, B Trollfors, T Lagergard, J Taranger, D Bryla, G Otterman, T Cramton, Y Yang, C B Reimer, J B Robbins.   

Abstract

The safety and immunogenicity of Haemophilus influenzae type b (Hib) capsular polysaccharide (CPS) alone, or covalently bound to tetanus toxoid in saline solution (Hib-TT) or adsorbed onto AI(OH)3 (Hib-TT ads), were evaluated after one injection into 18- to 23-month-old healthy children in Sweden. No side reactions were elicited by Hib CPS; side reactions elicited by the two conjugates were similar and comparable to those reported for diphtheria and tetanus toxoids adsorbed. Hib-TT was the most immunogenic of the three vaccines, eliciting about 10-fold higher antibody levels than Hib CPS; of 28 vaccinees, all had greater than 1.0 microgram Ab/mL serum after immunization with Hib-TT. Increases of Hib CPS antibodies within immunoglobulin classes induced by the three vaccines were, in decreasing order, IgG greater than IgM greater than IgA. Within IgG subclasses, rises in IgG1 Hib CPS antibodies were the most frequent, followed by IgG2; some vaccinees with high postimmunization levels also had rises in IgG3 and one in IgG4. Immunization-induced Hib CPS antibodies were bactericidal. Hib-TT also elicited higher levels of tetanus toxoid antibodies than Hib-TT ads; these tetanus toxoid antibodies neutralized tetanus toxin in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361379     DOI: 10.1016/s0022-3476(88)80684-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 2.  Effectiveness of Haemophilus influenzae type b vaccines.

Authors:  D M Stieb; H H Frayha; A D Oxman; H S Shannon; B G Hutchison; F S Crombie
Journal:  CMAJ       Date:  1990-04-01       Impact factor: 8.262

3.  Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom.

Authors:  G Tudor-Williams; J Frankland; D Isaacs; R T Mayon-White; J A MacFarlane; D G Rees; E R Moxon
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

4.  Immunogenicity and tolerance of H. influenzae type b, tetanus toxoid conjugate vaccine given concurrently or in combination.

Authors:  A Kumar; A K Dutta; A Saili; S Nangia; R Dutta
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

5.  Development of serum antibodies of the immunoglobulin G class and subclasses against the capsular polysaccharide of Haemophilus influenzae type b in children and adults with invasive infections.

Authors:  B A Claesson; T Lagergård; B Trollfors
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

6.  Heavy-chain isotype patterns of human antibody-secreting cells induced by Haemophilus influenzae type b conjugate vaccines in relation to age and preimmunity.

Authors:  T Barington; L Juul; A Gyhrs; C Heilmann
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  A novel laser vaccine adjuvant increases the motility of antigen presenting cells.

Authors:  Xinyuan Chen; Pilhan Kim; Bill Farinelli; Apostolos Doukas; Seok-Hyun Yun; Jeffrey A Gelfand; Richard R Anderson; Mei X Wu
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

8.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

Authors:  S J Devi; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.

Authors:  E Torbicka; T Lagergård; B Trollfors
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.